These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23280225)

  • 1. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.
    Al-Khatib SM; Hellkamp A; Bardy GH; Hammill S; Hall WJ; Mark DB; Anstrom KJ; Curtis J; Al-Khalidi H; Curtis LH; Heidenreich P; Peterson ED; Sanders G; Clapp-Channing N; Lee KL; Moss AJ
    JAMA; 2013 Jan; 309(1):55-62. PubMed ID: 23280225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defibrillator implantations for primary prevention in the United States: Inappropriate care or inadequate documentation: Insights from the National Cardiovascular Data ICD Registry.
    Kaiser DW; Tsai V; Heidenreich PA; Goldstein MK; Wang Y; Curtis J; Turakhia MP;
    Heart Rhythm; 2015 Oct; 12(10):2086-93. PubMed ID: 25982720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.
    Adabag S; Patton KK; Buxton AE; Rector TS; Ensrud KE; Vakil K; Levy WC; Poole JE
    JAMA Cardiol; 2017 Jul; 2(7):767-774. PubMed ID: 28724134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
    Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
    J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria?
    Daugherty SL; Peterson PN; Wang Y; Curtis JP; Heidenreich PA; Lindenfeld J; Vidaillet HJ; Masoudi FA;
    Am Heart J; 2009 Aug; 158(2):224-9. PubMed ID: 19619698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.
    Steinberg BA; Al-Khatib SM; Edwards R; Han J; Bardy GH; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Hallstrom A; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LY; Sanders GD
    JACC Heart Fail; 2014 Dec; 2(6):623-9. PubMed ID: 25306452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.
    Pun PH; Hellkamp AS; Sanders GD; Middleton JP; Hammill SC; Al-Khalidi HR; Curtis LH; Fonarow GC; Al-Khatib SM
    Nephrol Dial Transplant; 2015 May; 30(5):829-35. PubMed ID: 25404241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.
    Poole JE; Olshansky B; Mark DB; Anderson J; Johnson G; Hellkamp AS; Davidson-Ray L; Fishbein DP; Boineau RE; Anstrom KJ; Reinhall PG; Packer DL; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2020 Jul; 76(4):405-415. PubMed ID: 32703511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
    Hess PL; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton A; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders G
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2):179-86. PubMed ID: 25669833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Chen J; Johnson G; Hellkamp AS; Anderson J; Mark DB; Lee KL; Bardy GH; Poole JE
    J Am Coll Cardiol; 2013 May; 61(21):2161-8. PubMed ID: 23541974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of patients with indication for a implantable defibrillator for primary prevention of death.
    Hadid C; Avellana P; Di Toro D; Gomez CF; Visser M; Prieto N
    Arq Bras Cardiol; 2008 May; 90(5):311-5. PubMed ID: 18516400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.
    Bilchick KC; Wang Y; Cheng A; Curtis JP; Dharmarajan K; Stukenborg GJ; Shadman R; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; Swedberg K; O'Conner C; Levy WC
    J Am Coll Cardiol; 2017 May; 69(21):2606-2618. PubMed ID: 28545633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Friedman DJ; Al-Khatib SM; Zeitler EP; Han J; Bardy GH; Poole JE; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LYT; Sanders GD
    Am Heart J; 2017 Sep; 191():21-29. PubMed ID: 28888266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
    Sharma A; Al-Khatib SM; Ezekowitz JA; Cooper LB; Fordyce CB; Michael Felker G; Bardy GH; Poole JE; Thomas Bigger J; Buxton AE; Moss AJ; Friedman DJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Peterson ED; Inoue LYT; Sanders GD
    Eur J Heart Fail; 2018 Jun; 20(6):1031-1038. PubMed ID: 29761861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.
    Schrage B; Uijl A; Benson L; Westermann D; Ståhlberg M; Stolfo D; Dahlström U; Linde C; Braunschweig F; Savarese G
    Circulation; 2019 Nov; 140(19):1530-1539. PubMed ID: 31476893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.
    Pun PH; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Hallstrom A; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Hess PL; Inoue LY; Sanders GD
    Am J Kidney Dis; 2014 Jul; 64(1):32-9. PubMed ID: 24518128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure.
    Chen CY; Stevenson LW; Stewart GC; Bhatt DL; Desai M; Seeger JD; Williams L; Jalbert JJ; Setoguchi S
    BMJ; 2015 Jul; 351():h3529. PubMed ID: 26174233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study.
    Proclemer A; Muser D; Campana A; Zoni-Berisso M; Zecchin M; Locatelli A; Brieda M; Gramegna L; Santarone M; Chiodi L; Mazzone P; Rebellato L; Facchin D
    Int J Cardiol; 2013 Sep; 168(2):1416-21. PubMed ID: 23287697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.